Immunotherapy: PI3Kδ inhibition lifts the breaks on antitumour immunity

Nature Reviews Clinical Oncology

Volumn 11, Issue 8, 2014, Pages 442-

  Killock, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; UNCLASSIFIED DRUG;

BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL POPULATION; EFFECTOR CELL; ENZYME INHIBITION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ENZYME INHIBITORS; IMMUNE TOLERANCE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; T-LYMPHOCYTES, REGULATORY;

EID: 84905366154     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.112     Document Type: Note

References (1)

1. Ali, K. et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature doi:10.1038/nature13444